New frontiers in the treatment of systemic juvenile idiopathic arthritis [version 1; referees: 2 approved]

• Main Authors: Susan Canny, Elizabeth Mellins
• Format: Article
• Language: English
• Published: F1000 Research Ltd 2017-06-01
• Series: F1000Research
• Subjects: Clinical Immunology; Drug Discovery & Design; Immune & Inflammatory Rheumatic Diseases (incl. Arthritis); Innate Immunity; Leukocyte Signaling & Gene Expression
• Online Access: https://f1000research.com/articles/6-971/v1

Systemic juvenile idiopathic arthritis (sJIA) and its most significant complication, macrophage activation syndrome (MAS), have traditionally been treated with steroids and non-steroidal anti-inflammatory medications. However, the introduction of biologic medications that inhibit specific cytokines, such interleukins 1 and 6, has changed the treatment paradigm for sJIA patients. In this review, we discuss the therapies currently used in the treatment of sJIA as well as novel targets and approaches under consideration, including mesenchymal stromal cell therapy and JAK inhibitors. We also discuss targeting cytokines that have been implicated in MAS, such as interferon gamma and interleukin 18.